Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-24T21:38:44.041Z Has data issue: false hasContentIssue false

2.35 - Vilazodone

from SSRI/5HT1A Partial Agonist Antidepressants

Published online by Cambridge University Press:  19 October 2021

Edited by
Michael Cummings  and
Stephen Stahl
Michael Cummings
Affiliation:
University of California, Los Angeles
Stephen Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Typical or first-generation antipsychotic (FGA)

Type
Chapter
Information
Management of Complex Treatment-resistant Psychotic Disorders , pp. 265 - 268
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allergan USA Inc. (2020). Vilazodone Package Insert. Madison, New Jersey.Google Scholar
Schwartz, T. L., Siddiqui, U. A., Stahl, S. M. (2011). Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther Adv Psychopharmacol, 1, 81–87.CrossRefGoogle ScholarPubMed
Gaynes, B. N., Rush, A. J., Trivedi, M. H., et al. (2008). The STAR*D study: treating depression in the real world. Clevel Clin J Med, 75, 57–66.CrossRefGoogle ScholarPubMed
Croft, H. A., Pomara, N., Gommoll, C., et al. (2014). Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry, 75, e1291–e1298.CrossRefGoogle ScholarPubMed
Citrome, L. (2012). Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract, 66, 356–368.CrossRefGoogle ScholarPubMed
Mathews, M., Gommoll, C., Chen, D., et al. (2015). Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol, 30, 67–74.CrossRefGoogle ScholarPubMed
California Department of State Hospitals. (2019). DSH Psychotropic Medication Policy: SSRI Protocol. Sacramento, California.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Vilazodone
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Vilazodone
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Vilazodone
  • Edited by Michael Cummings, University of California, Los Angeles, Stephen Stahl, University of California, San Diego
  • Book: Management of Complex Treatment-resistant Psychotic Disorders
  • Online publication: 19 October 2021
Available formats
×